GT-04686 — Regulatory decision
Q4 2026
GT-04686 initial target indication expected in Q4 2026 .Source filing
GANX biotech catalysts & pipeline
GAIN THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
rexaceract — Full data
Q4 2026
Final results from Phase 1b clinical study of rexaceract expected in Q4 2026.Source filing
rexaceract — Conference presentation
Oct 4–Oct 8
Mr. Mack continued, "We remain focused on completing the ongoing nine-month extension of our Phase 1b study, with final data expected to be presented at the International Congress of Parkinson's Disease and Movement Disorders in Korea in October 2026, while advancing preparations for our Phase 2 clinical program."Source filing